newsfilter
← Earnings
Earnings Releases·

Mentari Therapeutics, Inc. — Nine Months Ended September 30, 2026 Earnings Summary

  • Reported a net loss of $62.996 million for the nine months ended September 30, 2026, driven by a significant increase in R&D expenses to $57.709 million from $6.101 million in the prior period, resulting in a net loss per share of $(12.56).
  • Completed a merger with InMed Pharmaceuticals Inc. on November 6, 2026, accompanied by a "Mentari Pre-Closing Financing" that raised approximately $490.0 million in aggregate gross proceeds to fund future operations.
  • Executed multiple strategic agreements with Paragon on July 1, 2026, covering MT-001, MT-002, MT-003, MT-004, and MT-005, committing to potential milestone payments totaling up to $44.5 million across clinical and regulatory tiers.
  • Cash and cash equivalents decreased to $45.791 million as of September 30, 2026, while total liabilities rose to $78.608 million primarily due to a $49.980 million related-party note payable; management expects existing cash and merger proceeds to fund operations for at least twelve months.
Company
MENTARI THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology